Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial

Background: One-week triple therapy has been suggested to be superior to tw o-week omeprazole-clarithromycin therapy for the cure of Helicobacter pylor i infection. However, direct comparisons of the two treatments are scarce. Aim: To compare triple with dual therapy for H. pylori infection in the pri mary care setting. Methods: One hundred and forty-five patients with duodenal ulcer and H. pyl ori infection were randomized to receive omeprazole 20 mg b.d. and clarithr omycin 500 mg t.d.s. for 14 days (OC14 group, 69 patients) or omeprazole 20 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 7 days (O CA7 group, 76 patients). Eradication was evaluated by the C-13-urea breath- test. Results: Intention-to-treat analysis showed a cure rate of 48% (95% CI: 36- 60%) in the OC14 group, and 71% (95% CI: 59-80%) in the OCA7 group (P = 0.0 004). Per protocol analysis showed cure rates of 51% (95% CI: 38-63%, 33/65 patients) and 82% (95% CI: 70-90%, 54/66 patients), respectively (P = 0.00 01). There were no significant differences in compliance or side-effects. Conclusion: One-week twice-daily triple therapy is superior to 2-week dual therapy, but the cure rate in primary care was far below 90%.